Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$12.00
52W Range
$5.40 - $32.55
50D Avg
$8.80
200D Avg
$9.21
Market Cap
$12.81M
Avg Vol (3M)
$32.02K
Beta
-
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Performance
Peer Comparison
Ticker | Company |
---|---|
SNTI | Senti Biosciences, Inc. |
ENOB | Renovaro Biosciences Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
MNPR | Monopar Therapeutics Inc. |
CNTA | Centessa Pharmaceuticals plc |
IKNA | Ikena Oncology, Inc. |
IKT | Inhibikase Therapeutics, Inc. |
XCUR | Exicure, Inc. |
FHTX | Foghorn Therapeutics Inc. |
MLYS | Mineralys Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
ANTX | AN2 Therapeutics, Inc. |
HCWB | HCW Biologics Inc. |
GPCR | Structure Therapeutics Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
NVCT | Nuvectis Pharma, Inc. |
ELYM | Eliem Therapeutics, Inc. |